Financials Negative

2026-05-30 19:56

Consolidated Revenue ₹14.20 Cr vs ₹12.29 Cr (▲15.5% YoY), EBITDA ₹4.45 Cr vs ₹5.02 Cr (▼11.3% YoY), PAT ₹-5.16 Cr vs ₹1.06 Cr (▼ from profit to loss). EBITDA Margin 31.3% vs 40.8% (▼950 bps).

Financials Negative

2026-05-30 19:54

CRITICAL RED FLAG DETECTED

Consolidated Revenue ₹14.20Cr vs ₹12.29Cr (▲15.54% YoY), EBITDA ₹4.45Cr vs ₹5.02Cr (▼11.30% YoY), PAT (Loss) ₹5.16Cr vs ₹1.06Cr (▼585.80% YoY). EBITDA Margin 31.33% vs 40.81% (▼948bps).

Financials Negative

2026-05-30 19:50

Consolidated Revenue ₹14.20 Cr vs ₹12.29 Cr (▲15.54% YoY), EBITDA ₹4.48 Cr vs ₹5.17 Cr (▼13.33% YoY), PAT (₹5.16 Cr) vs ₹1.06 Cr (▼585.80% YoY, turning a profit into a significant loss). EBITDA Margin 31.54% vs 42.05% (▼1051bps). The board also approved the re-appointment of Mr. Kalyan Ram Mangipudi as Whole-time Director for 5 years and the appointment of a consultant for a proposed Scheme of Arrangement/Amalgamation.

Governance Neutral

2026-05-29 21:50

Vivo Bio Tech Limited announced the postponement of its Board Meeting from May 29, 2026, to May 30, 2026. The meeting is scheduled to consider and approve the Audited Standalone & Consolidated Financial Results for the Fourth Quarter and Year ended March 31, 2026, and the amalgamation of M/s. Shri Shri Resorts Private Limited with Vivo Bio Tech Limited. The trading window remains closed until June 01, 2026.

Governance Neutral

2026-05-25 17:39

Vivo Bio Tech Limited announced a Board Meeting scheduled for May 29, 2026. The agenda includes considering and approving the Audited Standalone & Consolidated Financial Results for the Fourth Quarter and year ended March 31, 2026, and considering and approving the amalgamation of M/s. Shri Shri Resorts Private Limited with Vivo Bio Tech Limited. The trading window for the company's securities will remain closed until May 31, 2026.

Routine Positive

2026-05-19 15:56

Vivo Bio Tech Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, as per Regulation 24A of SEBI (LODR) Regulations, 2015. The report confirms that the company has fully complied with all applicable SEBI regulations and guidelines, with no non-compliances, observations from the Practicing Company Secretary, or instances of statutory auditor resignation during the review period.

Routine Neutral

2026-04-13 15:21

Vivo Bio Tech submitted a report on re-lodgement of physical share transfer requests for the period ended March 2026. The report, from Aarthi Consultants Private Limited, indicates NIL requests were received, processed, approved, or rejected during the month.

Routine Neutral

2026-04-07 12:32

Vivo Bio Tech Limited submitted a certificate under SEBI Regulation 74(5) for Jan 01, 2026, to Mar 31, 2026, confirming compliance with dematerialization and share transfer requirements.

Routine Neutral

2026-04-06 11:17

New Filing detected. See link for details.

Routine Neutral

2026-03-27 12:10

Vivo Bio Tech Limited announced the closure of the trading window for insiders from April 01, 2026, until 48 hours after the declaration of the Audited Standalone and Consolidated Financial Results for the fourth quarter and year ended March 31, 2026.

Financials Positive

2026-02-13 19:10

Consolidated Revenue ₹1,351.30 Lacs vs ₹1,221.25 Lacs (▲10.65% YoY), EBITDA ₹549.45 Lacs vs ₹553.87 Lacs (▼0.79% YoY), PAT ₹124.81 Lacs vs ₹82.00 Lacs (▲52.20% YoY). EBITDA Margin 40.66% vs 45.35% (▼469 bps).

Financials Positive

2026-02-13 19:09

Consolidated Revenue ₹13.51Cr vs ₹12.21Cr (▲10.7% YoY), EBITDA ₹5.49Cr vs ₹5.54Cr (▼0.8% YoY), PAT ₹1.25Cr vs ₹0.82Cr (▲52.2% YoY). EBITDA Margin 40.7% vs 45.4% (▼470bps).

Routine Neutral

2026-02-09 12:09

Vivo Bio Tech Limited announced the newspaper publication of a notice for a special window (Feb 01, 2026 to April 30, 2026) for re-lodgement of transfer requests and dematerialisation of physical shares, as per SEBI regulations.

Governance Neutral

2026-02-02 12:32

Vivo Bio Tech Limited announced a Board Meeting on February 13, 2026, to approve the un-audited standalone & consolidated financial results for Q3 and 9 months ended December 31, 2025. The trading window will remain closed until February 15, 2026.

511509

VIVO BIO TECH LTD

Filing History

Unlock Full History